Ms. Kogan is a biotechnology executive with over twenty years of experience focused on building fast growing publicly traded companies in regulated industries.

During her career, Ms. Kogan has provided leadership for transactions valued at more than $10 billion by developing the strategic, operating, and legal direction for publicly traded biotechnology and pharmaceutical companies through joint ventures, partnerships, mergers and acquisitions, and other business combinations with companies including Pfizer Inc., Merck & Co., Inc., Alpharma, Inc., Otsuka Pharmaceutical, Co. Ltd., and Takeda Pharmaceutical, Co. Ltd.

Ms. Kogan has provided legal, government relations, and compliance leadership for biotechnology and pharmaceutical companies in a broad range of therapeutic areas including cardiovascular, abuse deterrent technology platform, neuroscience, and oncology. Ms. Kogan has played a key role in leading companies through the development of a robust research and development pipeline, successful product launches, commercialization, and mergers and acquisitions.

Ms. Kogan is a graduate of the Southwestern Law School SCALE Program. Ms. Kogan graduated cum laude from Columbia University, Barnard College, with a degree in economics.